Clinical Trial Update: Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion [Phase 2, Phase 3]

View source ↗

Summary

The registry protocol to track subjects after completion of the VTI-206 trial (Phase 2/Phase 3) for acute liver failure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Failure

Drugs mentioned

• VTI-206

Snippet

Sponsor: Vital Therapies, Inc. | Conditions: Acute Liver Failure | Phase 2, Phase 3 | Status: WITHDRAWN